MENUCLOSE

 

Connect with us

Tag : clinical trial sites

ArcheMedX Releases New Oncology Findings Ahead Of ESMO Congress Revealing Clinician Readiness

2021 was a historic year in the battle to defeat cancer.   More novel cancer treatments became available than ever before with the number of Oncology specific clinical trials also reaching an all-time high, up 56% from 2016 and mostly focused on rare cancer indications. With global spending on Oncology expected to exceed $300

Successful Clinical Trial Management Now Means Accepting Complexity. Here’s How to Deal with It.

If it shocks you to hear that clinical trials are getting more complex, you haven’t been paying attention. Specifically, we’re collecting more endpoints. We’re performing more procedures. We’re increasing nearly every executional variable, like the number of countries, the number of sites, the number of visits per patient, and the

A Decentralized Clinical Trial Requires Training at Scale. Here’s What That Means.

The decentralized clinical trial is one of the most talked-about emerging trends in the life sciences industry. These sorts of clinical trials present immense benefits, as we wrote about in a recent blog. If executed well, the decentralized clinical trial design could both reduce resource consumption and accelerate treatments arrival to

When Seeking Diversity during Site Selection, Look Beyond Historical Data to Discover Untapped Patient Populations

We recently spoke with Liz Beatty, Chief Strategy Officer at Inato about how the company is disrupting the industry's approach to site selection. The company is headquartered in Paris, France, with US operations based in New York City, NY. Here are some of the most interesting excerpts from our discussion: ArcheMedX: You

Choosing a Solution to Train Clinical Trial Site Staff Virtually? Start With this Checklist.

Choosing the right way to train clinical trial staff is complex and exhausting under normal circumstances. Today’s immense pressure to accommodate new virtual working styles across investigator meetings, site selection, and site initiation visits magnifies those challenges. As we revealed in our recent report, clinical operations leaders are adopting virtual tools